SanegeneBio
Address: 300 TradeCenter, Boston,About Us
Sanegene Bio is a clinical-stage, fully integrated biotechnology company backed by a syndicate of private equity investors. We are focused on discovering and developing best-in-class genetic medicines for obesity, cardiometabolic, and autoimmune diseases using RNA interference (RNAi) technology. Founded in 2021 by industry veterans with deep RNAi expertise, SanegeneBio is headquartered in Boston, with R&D operations in both the U.S. and China. Our proprietary technology platform, LEAD™ (Ligand and Enhancer Assisted Delivery), enables tissue-specific silencing of disease-driving genes in the liver, adipose tissue, muscle, and immune cells—achieved through safe, infrequent subcutaneous dosing. Sanegene Bio is committed to advancing transformative RNAi therapies that address global unmet medical needs.
Sectors
- Collaborations & Partnerships- R&D
- Collaborations & Partnerships-Licensing
- Collaborations & Partnerships-Manufacture
- Proprietary Research & Manufacture
- Gene/RNA Delivery Technology
- Drug Delivery
Categories
- Biologics
- Biotechnology
- Drug Discovery Services
- Platform Technology-Drug Discovery
- RNAi Technology
- Clinical Development-Pipeline
- Gene Delivery Technology
- Gene Delivery Technology- Non-Viral
- Nucleic Acids
News
SanegeneBio Enters $1.5 Billion Exclusive Global License Agreement with Genentech for RNAi Program
SanegeneBio and Genentech entered a global licensing agreement aimed at advancing an RNA interference (RNAi) therapeutic program, underscoring continued pharmaceutical interest in genetic medicines that can be scaled beyond rare diseases.
Source: The Partnership Tree | https://www.pharmaservicesdirectory.com